He estimates COVID-19 vaccine sales next year will fall to ~$2.0B, lower than the $2.6 billion predicted ... Foroohar lowered ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters -- they're not just another dose of ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...

Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s ...

Investors are digesting a fresh interest rate cut from the Federal Reserve as the impact of Trump's expected policies also remains in focus.

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Benchmark equity indices Sensex and Nifty50 slipped into the red on Thursday after logging gains in the previous session following Republican Donald Trump's win in the US presidential race. Investors ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Shares of Moderna (NASDAQ:MRNA) traded ~7% higher in the premarket on Thursday after the company swung back to profits on ...